Postmarketing Periodic Reports Should Be Biannual, Not Quarterly - Ligand
Executive Summary
Postmarketing periodic adverse event reports should be required every six months following product approval instead of every three months, Ligand suggested in recent comments on FDA's draft guidance "Postmarketing Safety Reporting for Human Drug and Biological Products Including Vaccines."